Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Portland, OR
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Beaver, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Beaver, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Danville, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Danville, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Doylestown, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Doylestown, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Erie, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Jersey Shore, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Jersey Shore, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Lewistown, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Lewistown, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Philipsburg, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Philipsburg, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Pittsburgh, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Port Matilda, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Port Matilda, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Sayre, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Sayre, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Scranton, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Scranton, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Sellersville, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Sellersville, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Wilkes-Barre, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
York, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
York, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Spartanburg, SC
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Rapid City, SD
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Sioux Falls, SD
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Bristol, TN
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Johnson City, TN
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Amarillo, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Amarillo, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Corpus Christi/Texas, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Corpus Christi/Texas, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Dallas, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Georgetown, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Georgetown, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Harker Heights, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Harker Heights, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Houston, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Plano, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Plano, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
San Antonio, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Victoria, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Victoria, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Draper, UT
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Draper, UT
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Burke, VA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Burke, VA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Norfolk, VA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Winchester, VA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Winchester, VA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Kirkland, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Kirkland, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Olympia, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Olympia, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Renton, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Seattle, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Spokane, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Tacoma, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Walla Walla, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Walla Walla, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Wenatchee, WA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Wausau, WI
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Wausau, WI
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Adrogue,
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Adrogue,
Click here to add this to my saved trials
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Ocala, FL
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Ocala, FL
Click here to add this to my saved trials
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Albuquerque, NM
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Syracuse, NY
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Dallas, TX
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Adrogue,
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Adrogue,
Click here to add this to my saved trials
SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions
SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions of Induced Hypoxia as Compared to Arterial Blood CO-Oximetry
Status: Enrolling
Updated:  7/9/2015
Clinimark
mi
from
Louisville, CO
SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions
SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions of Induced Hypoxia as Compared to Arterial Blood CO-Oximetry
Status: Enrolling
Updated: 7/9/2015
Clinimark
mi
from
Louisville, CO
Click here to add this to my saved trials
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Gilbert, AZ
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials